WHAT IS CLAIMED IS:

1. A method of increasing adeno-associated virus 9 ABCD1 (AAV9-ABCD1) vector titers in transfected producer cells grown in culture, said method comprising the steps of:

i) incubating a nucleic acid sequence that is complementary to an mRNA encoding ATP binding cassette subfamily D member 1 (ABCD1) with the cells, and

ii) transfecting an AAV9 vector comprising a nucleotide sequence encoding ABCD1 into the cells (AAV9-ABCD1 vector), wherein the amount of ABCD1 mRNA expressed from the AAV9 vector is decreased, thereby increasing AAV9-ABCD1 vector yield in cell lysate and/or media by 1 fold to 50 fold compared to a reference standard.

2. The method of claim 1, wherein the nucleic acid sequence that is complementary to an mRNA encoding ABCD1 is an interfering RNA.

3. The method of claim 2, wherein the interfering RNA is an shRNA or siRNA.

4. The method of claim 3, wherein the siRNA comprises SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or a combination thereof.

5. The method of claim 1, wherein the reference standard comprises AAV9-ABCD1 vector yield in cell lysate and/or media from producer cells that were not incubated with a nucleic acid sequence that is complementary to an mRNA encoding ABCD1.

6. Use of a composition comprising purified AAV9-ABCD1 vector obtained from the producer cells of claim 1 in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD), wherein the purified AAV9-ABCD1 vector comprises a nucleic acid sequence that encodes an mRNA sequence comprising SEQ ID NO: 9.

7. The use of claim 6, wherein the composition comprising purified AAV9-ABCD1 vector is to be administered by intrathecal administration.

8. Use of an adeno-associated virus 9 (AAV 9) vector encoding an ATP binding cassette subfamily D member 1 (ABCD1) in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD), wherein said vector is to be administered by

intrathecal administration, and wherein the AAV9 vector comprises a nucleic acid sequence that encodes an mRNA sequence comprising SEQ ID NO: 9.

9. The use of claim 8, wherein the intrathecal administration is to be mediated by a pump.

10. The use of claim 8, wherein the dose of vector is $1x10^{13}$GC to $10x10^{13}$GC.

11. Use of an AAV9 vector encoding ABCD1 in the manufacture of a medicament for the treatment of X-linked adrenoleukodystrophy (X-ALD), wherein the treatment comprises providing ATP binding cassette subfamily D member 1 (ABCD1), wherein said vector is to be administered by intrathecal administration, and wherein ABCD1 expression from said vector in a central nervous system of a subject is more than ABCD1 expression from said vector in peripheral organs of the subject and wherein the AAV9 vector comprises a nucleic acid sequence that encodes an mRNA sequence comprising SEQ ID NO: 9.

12. The use of claim 11, wherein ABCD1 expression from said vector in the central nervous system is 3 fold higher than expression of ABCD1 in a central nervous system of an untreated subject that does not have X-ALD.

13. The use of claim 12, wherein the ABCD1 expression from said vector in the peripheral organs of the subject is 90% less than expression of ABCD1 in peripheral organs of an untreated subject that does not have X-ALD.

14. The vector for the use of claim 11, wherein the intrathecal administration is mediated by a pump.